Back to Browse Journals » Cancer Management and Research » Volume 1

Bortezomib in the management of multiple myeloma

Authors Jacob P Laubach, Constantine S Mitsiades, Teru Hideshima, et al

Published Date September 2009 Volume 2009:1 Pages 107—117

DOI http://dx.doi.org/10.2147/CMAR.S4555

Published 8 September 2009

Jacob P Laubach, Constantine S Mitsiades, Teru Hideshima, Robert Schlossman, Dharminder Chauhan, Nikhil Munshi, Irene Ghobrial, Nicole Carreau, Kenneth C Anderson, Paul G Richardson

Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA

Abstract: Multiple myeloma (MM) is a B-cell malignancy characterized by clonal expansion of plasma cells within the bone marrow, the presence of a serum and/or urine monoclonal protein, lytic bone lesions, and anemia. On a cellular level, the disease is characterized by complex interactions between tumor cells and the surrounding bone marrow microenvironment. Understanding of the relationship between malignant plasma cells and the microenvironment has sparked ongoing efforts to develop targeted therapeutic agents for treatment of this disease. The successful development of the first-in-class small-molecule proteasome inhibitor bortezomib occurred as a result of these efforts. This review focuses on the rationale for bortezomib therapy in the treatment of patients with newly diagnosed and relapsed MM, important treatment-related side effects, and future directions for use of bortezomib and other, emerging proteasome inhibitors.

Keywords: multiple myeloma, bortezomib, stem cell transplantation, peripheral neuropathy

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy

Paul Richardson, Constantine Mitsiades, Jacob Laubach, et al

Core Evidence 2009, 4:215-245

Published Date: 17 November 2009

Readers of this article also read:

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy

Rudolph M Navari

Cancer Management and Research 2009, 1:167-176

Published Date: 10 December 2009

The role of azacitidine in the management of myelodysplastic syndromes (MDS)

KS Götze, C Müller-Thomas, C Peschel

Cancer Management and Research 2009, 1:119-130

Published Date: 9 October 2009

Update on the management of prostate cancer with goserelin acetate: patient perspectives

Shandra Wilson

Cancer Management and Research 2009, 1:99-105

Published Date: 12 August 2009

Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron

Emilio Bajetta, Sara Pusceddu, Valentina Guadalupi, et al

Cancer Management and Research 2009, 1:89-97

Published Date: 10 August 2009

Evolving role of cetuximab in the treatment of colorectal cancer

Gunter Schuch, Sebastian Kobold, Carsten Bokemeyer

Cancer Management and Research 2009, 1:79-88

Published Date: 23 July 2009

Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer

Marta Vallee Cobham, Diana Donovan

Cancer Management and Research 2009, 1:69-77

Published Date: 29 June 2009

Is social support associated with improved clinical outcomes in geriatric lung cancer patients? Observations from North Central Cancer Treatment Group Studies N9921 and N0222

Aminah Jatoi, Shauna L Hillman, Katie L Allen Ziegler, Philip J Stella, et al.

Cancer Management and Research 2009, 1:61-68

Published Date: 17 June 2009

Validation of the cell cycle G2 delay assay in assessing ionizing radiation sensitivity and breast cancer risk

Jeff W Hill, Kristina Tansavatdi, Kristin L Lockett, Glenn O Allen, et al.

Cancer Management and Research 2009, 1:39-48

Published Date: 30 April 2009

TGFβ signaling supports survival and metastasis of endometrial cancer cells

XiuFen Lei, Long Wang, Junhua Yang, Lu-Zhe Sun

Cancer Management and Research 2009, 1:15-24

Published Date: 1 April 2009